news

Abbvie receives Orphan Drug Designation for Humira for the investigational treatment of hidradenitis suppurativa

1
SHARES

The US Food and Drug Administration (FDA) has granted Abbvie’s Humira® (adalimumab) Orphan Drug Designation for the investigational treatment of moderate-to-severe hidradenitis suppurativa (Hurley Stage II and Hurley Stage III disease), a painful, chronic inflammatory skin disease.

AbbVie’s supplemental Biologic License Application seeking FDA approval for the use of Humira in patients with moderate-to-severe hidradenitis suppurativa is currently under review with the agency. Humira is not currently approved by regulatory authorities for the treatment of hidradenitis suppurativa.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

Patients living with hidradenitis suppurativa have limited treatment options

“Patients living with hidradenitis suppurativa have limited treatment options and often experience severe, painful symptoms that can significantly impact their lives,” said Scott Brun, M.D., Vice President, Pharmaceutical Development, AbbVie. “We are committed to researching treatment options to address the unmet needs of the dermatology community and we are pleased that the FDA has issued this designation and recognises the treatment potential of Humira.”

Hidradenitis suppurativa, sometimes referred to as “acne inversa” by dermatologists, is a painful, chronic inflammatory skin disease for which there is no known cure and no approved medication. The disease is characterised by inflamed areas typically located around the armpits and groin, between the buttocks and under the breasts. A number of physical signs are associated with hidradenitis suppurativa – namely, painful abscesses and nodules, sinus tracts and scarring. The symptoms associated with hidradenitis suppurativa may lead to limited movement and psychological strain that impact the lives of patients.

Physicians typically assess the signs and symptoms of hidradenitis suppurativa on a scale developed from a clinical measure of severity called the Hurley Staging System. Hurley Stage II manifests with recurrent abscesses with sinus tracts and scarring, single or multiple widely separated lesions. In Hurley Stage III, patients present with either spread or interconnected abscesses.

For more information about Abbvie or Humira, please visit www.abbvie.com.

Related topics

Related organisations

Related drugs

Related diseases & conditions

Share via
Share via